# Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004

> **NIH NIH UM1** · KAISER FOUNDATION RESEARCH INSTITUTE · 2022 · $2,114,527

## Abstract

The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during
pregnancy or postpartum. The Seattle Children’s Research Institute, a subcontractor to the Kaiser Washington
VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The
NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the
Seattle Children’s Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for
the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.

## Key facts

- **NIH application ID:** 10523479
- **Project number:** 3UM1AI148373-03S6
- **Recipient organization:** KAISER FOUNDATION RESEARCH INSTITUTE
- **Principal Investigator:** LISA A JACKSON
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,114,527
- **Award type:** 3
- **Project period:** 2022-04-07 → 2024-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10523479

## Citation

> US National Institutes of Health, RePORTER application 10523479, Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004 (3UM1AI148373-03S6). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10523479. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*